Library
A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial.
7 March 2019. doid: 10.1210/jc.2018-01364
de Boon WMI, van Esdonk MJ, Stuurman FE, Biermasz NR, Pons L, Paty I, Burggraaf J
View publicationA somatostatin-dopamine chimera (BIM23B065) was under investigation to reduce GH secretion for the treatment of pituitary adenomas.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
